Editas Medicine, Inc. (EDIT) intrinsic value & 10-year financials
Editas Medicine, Inc. (EDIT) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 23.5% a year to $40.5M, with an average return on invested capital of -180.2%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.35
- Market cap
- $208.6M
- Revenue (FY2025)
- $40.5M
- Revenue growth (10-yr CAGR)
- 23.5%
- ROIC (10-yr avg)
- -180.2%
- Free cash flow (FY2025)
- -$165.8M
EDIT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $40.5M | -$160.1M | -$1.80 | -$165.8M | -394.9% | -1004.3% |
| FY2024 | $32.3M | -$237.1M | -$2.88 | -$219.1M | -777.2% | -152.0% |
| FY2023 | $78.1M | -$153.2M | -$2.02 | -$136.9M | -216.6% | -67.4% |
| FY2022 | $19.7M | -$220.4M | -$3.21 | -$181.5M | -1146.3% | -73.1% |
| FY2021 | $25.5M | -$192.5M | -$2.83 | -$171.8M | -756.1% | -60.4% |
| FY2020 | $90.7M | -$116.0M | -$1.98 | -$187.0M | -148.6% | -72.3% |
| FY2019 | $20.5M | -$133.7M | -$2.68 | -$46.8M | -686.4% | -147.5% |
| FY2018 | $31.9M | -$110.0M | — | -$50.5M | -356.1% | -82.2% |
| FY2017 | $13.7M | -$120.3M | — | -$11.5M | -873.6% | -70.2% |
| FY2016 | $6.1M | -$97.2M | — | -$53.7M | -1605.6% | -72.2% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Editas Medicine, Inc. is a consistent compounder, expanding top-line revenue at 23.5% annually over the past decade.
Editas Medicine, Inc. has historically struggled to out-earn its cost of capital, averaging just -64.3% ROIC.
Editas Medicine, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Editas Medicine, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-59.79 per share.